Success Stories: Precision in the Genome: EB2-NIW Approved for South Korean Bioengineer Advancing Gene Therapy and Disease Modeling

Client’s Testimonial:

“Overall, the process was super smooth, and attorneys were very helpful and informative in answering whatever questions I had throughout the process. I highly suggest anyone considering applying for NIW use the Chen Immigration Attorneys service.”

On May 28^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Scholar in the Field of Bioengineering (Approval Notice).

General Field: Bioengineering

Position at the Time of Case Filing: Postdoctoral Scholar

Country of Origin: South Korea

State of Residence at the Time of Filing: California

Approval Notice Date: May 28^th, 2025

Processing Time: 8 months, 9 days (Premium Processing Requested)

Case Summary:

A gifted researcher from South Korea, whose work is reshaping the future of genetic medicine and molecular diagnostics, has received his EB2-NIW approval with the help of our firm. With expertise in gene editing, protein engineering, and non-invasive gene delivery systems, this bioengineer is spearheading innovations that make gene therapy safer, more targeted, and more effective. His petition, filed under premium processing, received approval in just over seven months, validating the national interest of his contributions.

A Mission to Safely Rewire the Genome

With a Ph.D. in bioengineering, the client’s proposed endeavor focuses on the development of advanced biological tools to interface with cells and tissues at the genetic and molecular level. His work aims to:

● Advance safer and more precise gene editing through improved CRISPR base editors
● Engineer synthetic protein biomarkers to monitor brain activity noninvasively
● Refine viral vector delivery systems for targeted gene therapies

His research holds particular promise for neurological diseases, many of which remain incurable due to the complexity of gene delivery into brain tissue. At the time of filing, he had already secured a research role at a leading U.S. research institution to continue advancing his work in neuroengineering and gene therapy development.

Research Recognized by Global Peers

The client has authored 8 peer-reviewed journal articles, 5 first-authored conference abstracts, and 2 published patent applications, with a total of 163 citations to date. Several of his articles rank among the top 10% and even top 1% most-cited papers in molecular biology and genetics for their year of publication, including:

● Science Advances (2020) – 82 citations (top 10%)
● Advanced Drug Delivery Reviews (2021) – 29 citations (top 10%)
● Gene Therapy (2024) – 5 citations (top 1%)
● Nature Biotechnology (2024) – Published work on synthetic biomarkers

His articles have influenced studies published in prestigious journals such as Nature Biotechnology, Nature Communications, BMC Biology, and Neural Regeneration Research, underscoring his global scientific footprint.

Tackling Neurological Disease with Molecular Precision

The significance of the client’s work lies in his ability to enhance gene therapy’s accuracy and safety, particularly in the brain. A project that exemplifies this involved developing a high-precision CRISPR base editor that minimizes off-target mutations. This tool achieved a 6,000-fold improvement in accuracy, a crucial advance for treating genetic disorders.

Another initiative focused on creating non-invasive methods for tracking gene expression in the brain. By engineering biomarkers that could be detected via blood tests, and using focused ultrasound to target specific brain regions, his techniques offer new hope for treating neurodegenerative conditions without invasive surgery.

A Voice of Authority in the Field

An associate professor of bioengineering who collaborated directly with the client praised his ingenuity:

“[Client’s] improvements to CRISPR base editing have provided a foundation for safer therapeutic applications. His precision and specificity breakthroughs are advancing biomedicine and supporting U.S. leadership in gene editing research.”

This perspective is echoed by additional independent letters from experts at major U.S. universities, all of whom confirmed the originality, reliability, and national impact of the client’s work.

Supported by Prestigious Scientific Institutions

The client’s work has received funding from:

1. The National Institutes of Health (NIH)
2. The Welch Foundation
3. The David and Lucile Packard Foundation
4. The Cancer Prevention and Research Institute of Texas (CPRIT)

These organizations fund only projects that align with national scientific priorities—from cancer prevention and chemical biology to neurogenomics and therapeutic development.

Contributing to Critical and Emerging Technologies

The client’s work falls under several Critical and Emerging Technology (CET) categories recognized by the U.S. National Science and Technology Council, including:

● Synthetic biology
● Genetic medicine
● Viral vector design and delivery systems
● Precision molecular diagnostics

By aligning with CET priorities, his efforts support not only public health but also U.S. economic resilience and technological competitiveness.

Approval That Affirms National Relevance

Filed on September 19, 2024, and approved on May 28, 2025, this EB2-NIW petition demonstrated:

● The endeavor’s substantial merit and national importance
● The client’s positioning to advance it through past research and future plans
● That a waiver of the job offer requirement would benefit the United States

We believe that science done well can reshape lives, and the client’s approval exemplifies this. With groundbreaking contributions to bioengineering, gene editing, and neurological diagnostics, this researcher’s journey from South Korea to the United States now continues in a way that promises real impact for patients, researchers, and public health alike.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.